Clinical trial NCT04671602: Learning to Evaluate Blood Pressure at Home (LEANBH)
Official title: Implementing LEANBH Ambulatory Integrated Blood Pressure Monitoring in Maternity Services
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypertension in Pregnancy
Lead sponsor: University College Cork
Sponsor class: OTHER
Collaborators: name: Science Foundation Ireland
First posted: 2020-12-17
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with an ongoing, confirmed intrauterine pregnancy who have borderline high blood pressure or are at risk of developing high blood pressure in this pregnancy and are due to give birth in Cork University Maternity Hospital.

Brief summary: COVID-19 has highlighted important deficiencies in our health service where front line staff and pregnant women are being exposed to SARS-Cov-2 through assessments that could be conducted using Connected Health solutions, reducing risks of contracting or disseminating SARS-Cov-2. Currently, pregnant women are not attending GPs or hospitals for BP monitoring for fear of contracting SARS-Cov-2. Uncontrolled or unmonitored hypertension in pregnancy is associated with maternal and fetal morbidity and mortality. The aim of the study is to use home BP monitoring as an adjunct to standard care for women with borderline/suspected hypertension in pregnancy. To reduce the exposure risk for staff and pregnant women, we propose the immediate implementation of ambulatory automated self BP monitoring using the LEANBH platform- an existing integrated platform to monitor pregnant women.

Detailed description: The COVID-19 pandemic exposes our front-line staff to unnecessary risks in interacting with COVID-19 affected patients. Current care of pregnant women who have uncontrolled/unmonitored hypertension involves multiple visits to obstetric units for blood pressure checks. These visits put the women at risk of contracting or transmitting SARS-CoV-2 by bringing them into hospitals for checks which could otherwise be done remotely. Up to 20% of pregnant women will experience a hypertensive episode during pregnancy or the postpartum period. Uncontrolled or unmonitored hypertension in pregnancy may be associated with significant maternal and fetal morbidity and mortality including pre-eclampsia, stroke and stillbirth. The current management of suspected hypertension in pregnancy involves prolonged admission to hospital for BP monitoring or multiple visits to day assessment units or primary care physicians. All of these increase the risk of contracting or transmitting SARS-CoV-2. In addition, pregnant women with COVID-19 who are receiving inpatient care also require regular BP monitoring increasing the exposure risk for staff of contracting SARS-CoV-2. Pregnant women not attending GPs or hospitals for BP monitoring out of fear of contracting COVID-19 drastically increase their risk of suffering adverse effects from undiagnosed or uncontrolled hypertension. The ideal solution would be to facilitate inpatient or outpatient monitoring with reduced face to face contact between staff and infected patients. This would ensure a safer experience for all by reducing the risk of contracting SARS-CoV-2 while safely offering remote BP monitoring. LEANBH offers this safe alternative to direct hospital contact for pregnant women and staff by providing ambulatory automated self BP monitoring using the LEANBH integrated platform. This proposal will deliver immediate ambulatory BP self-monitoring performed remotely without need for direct physical contact, minimising risk of exposure to SARS-CoV-2 for staff and pregnant women.

Eligibility criteria: Inclusion Criteria:

* Aged 18 years or over.
* Ability to give informed consent.
* Mobile application compatible smartphone.
* Increased requirement for blood pressure monitoring in this pregnancy as determined by their treating obstetric team.
* Between 12 weeks of pregnancy and up to six weeks postpartum

Exclusion Criteria:

* Inability to give informed consent (language barrier)
* Confirmed Preeclampsia

Primary outcomes:
measure: Participant Satisfaction
timeFrame: 12-42 weeks gestation
Secondary outcomes:
measure: Clinical Escalation
timeFrame: 12-42 weeks gestation
measure: Adverse Events
timeFrame: 12 weeks gestation - 6 weeks postpartum
Other outcomes:
Locations:
city: Cork
country: Ireland
facility: Cork University Maternity Hospital
Study officials:
References: